Becton, Dickinson and Company (BDX)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

266.98

+3.29

(+1.25%)

As of 03:14PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	263.69
Open	263.08
Bid	266.82 x 800
Ask	266.92 x 800
Day's Range	262.61 - 267.50
52 Week Range	229.40 - 277.29
Volume	430,012
Avg. Volume	979,212

Market Cap	76.143B
Beta (5Y Monthly)	0.61
PE Ratio (TTM)	40.58
EPS (TTM)	6.58
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	3.48 (1.32%)
Ex-Dividend Date	Sep 08, 2022
1y Target Est	274.55

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BDX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Becton, Dickinson and Company
Analyst Report: Becton, Dickinson and CompanyBecton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Rating
Fair Value
Economic Moat
11 days agoMorningstar

All

Simply Wall St.
Becton Dickinson's (NYSE:BDX) five-year earnings growth trails the favorable shareholder returns
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
- Investors in N-able (NYSE:NABL) have unfortunately lost 25% over the last year
  Simply Wall St.
- The past year for Barratt Developments (LON:BDEV) investors has not been profitable
  Simply Wall St.
Zacks
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
PR Newswire
BD, Accelerate Diagnostics Announce Global Commercial Collaboration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.